Insider · CIK 0001953943
Benjamin Halladay
cfoofficer
Files at ACHV (ACHIEVE LIFE SCIENCES, INC.), ESPR (Esperion Therapeutics, Inc.). First filing Dec 18, 2024, latest Dec 18, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 9
$0 bought, $68k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Esperion Therapeutics, Inc. | $27k 7,337 shares | -2% | - | |
| 37Weak | Esperion Therapeutics, Inc. | $20k 7,046 shares | -1% | - | |
| 30Weak | Esperion Therapeutics, Inc. | $12 11 shares | -0% | - | |
| 37Weak | Esperion Therapeutics, Inc. | $8,328 7,229 shares | -2% | - | |
| 30Weak | Esperion Therapeutics, Inc. | $8 8 shares | -0% | - | |
| 37Weak | Esperion Therapeutics, Inc. | $5,242 3,535 shares | -1% | - | |
| 30Weak | Esperion Therapeutics, Inc. | $20 11 shares | -0% | - | |
| 30Weak | Esperion Therapeutics, Inc. | $20 9 shares | -0% | - | |
| 37Weak | Esperion Therapeutics, Inc. | $7,866 3,245 shares | -1% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | AGrant or award Stock Option (right to buy)derivative | +200,000 | $0.00 | $0 | 200,000 | 6 d ago |
| Oct 5, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | AGrant or award Restricted Stock Unit (RSU)derivative | +200,000 | $0.00 | $0 | 200,000 | 6 d ago |
| Dec 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -7,337 | $3.67 | $27k | 467,525 | Dec 18, 2025 |
| Sep 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -7,046 | $2.81 | $20k | 474,862 | Sep 18, 2025 |
| Jul 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -11 | $1.12 | $12 | 474,462 | Jul 18, 2025 |
| Jun 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -7,229 | $1.15 | $8,328 | 474,473 | Jun 18, 2025 |
| Apr 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -8 | $0.96 | $8 | 481,702 | Apr 21, 2025 |
| Mar 18, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -3,535 | $1.48 | $5,242 | 481,710 | Mar 19, 2025 |
| Mar 14, 2025 | ESPR Esperion Therapeutics, Inc. | AGrant or award Common Stock | +238,000 | $0.00 | $0 | 485,245 | Mar 17, 2025 |
| Mar 14, 2025 | ESPR Esperion Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +213,000 | $0.00 | $0 | 213,000 | Mar 17, 2025 |
| Feb 19, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -11 | $1.86 | $20 | 240,671 | Feb 20, 2025 |
| Jan 17, 2025 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -9 | $2.27 | $20 | 240,682 | Jan 21, 2025 |
| Dec 17, 2024 | ESPR Esperion Therapeutics, Inc. | SOpen-market sale Common Stock | -3,245 | $2.42 | $7,866 | 240,691 | Dec 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.